Dear Dr. Donohew:

Please refer to your supplemental new drug application dated September 5, 2008, received September 5, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Chantix (varenicline) Tablets 0.5 mg and 1 mg.

We acknowledge receipt of your submissions dated April 30 and July 15, 2009.

This supplemental new drug application provides for a Risk Evaluation and Mitigation Strategy (REMS) for Chantix (varenicline). The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the FDCA authorizes FDA to require the submission of a REMS if FDA becomes aware of new safety information and makes a determination that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks (section 505-1(a)).

Since Chantix (varenicline) was approved on May 10, 2006, we have become aware of postmarketing reports of neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, and suicidal thoughts or actions associated with Chantix (varenicline). This information was not available when Chantix (varenicline) was granted marketing authorization as an aid to smoking cessation treatment. We consider this information to be “new safety information” as defined in FDAAA.

Your revised proposed REMS, submitted on July 15, 2009 and appended to this letter, is approved. The REMS consists of the Medication Guide included with this letter and the timetable for submission of assessments of the REMS.

Your assessment of the REMS should include an evaluation of patients’ understanding of the serious risks of Chantix.

The requirements for assessments of an approved REMS under section 505-1(g)(3) include, in section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. You can
satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in Section 505-1(g)(2)(A) of FDCA.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission:

- **NDA 021928 REMS ASSESSMENT**
- **NEW SUPPLEMENT FOR NDA 021928**
  - PROPOSED REMS MODIFICATION
  - REMS ASSESSMENT
- **NEW SUPPLEMENT (NEW INDICATION FOR USE)**
  - FOR NDA 021928
  - REMS ASSESSMENT
  - PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Ayanna Augustus, Regulatory Project Manager, at ayanna.augustus@fda.hhs.gov or (301) 796-3980.
Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, M.D.
Director
Division of Anesthesia, Analgesia, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure:

1. REMS
2. Medication Guide
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-21928</td>
<td>SUPPL-11</td>
<td>PFIZER INC</td>
<td>CHANTIX</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BOB A RAPPAPORT
10/19/2009